Gordon brings over 30 years of experience in oncology, drug development, R and D and clinical and regulatory affairs for both biotechnology and larger biopharmaceutical companies.
Gordon joins Ayala from AbbVie, where he served as the vice president of Oncology Development.
During his time at AbbVie, Gordon oversaw the development and advancement of nearly 200 clinical studies in approximately 50 countries.
Previously, he was a divisional vice president of global oncology development, and before that the Global Project Head for PPD R and D, both at Abbott Laboratories.
Prior to that role, Gordon was the chief scientific officer and vice president of clinical affairs at Ovation Pharmaceuticals where he spearheaded the acquisition of five drugs from Abbott.
Gordon received his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine, where he also completed his residency and postdoctoral training as well as served as an Associate Professor of Medical Oncology.
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers.
Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).
Ayala's lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY).
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval